| dc.creator |
Ergene, Ulku |
|
| dc.creator |
Ozbalci, Demircan |
|
| dc.date |
2013-04-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:37:41Z |
|
| dc.date.available |
2025-02-25T10:37:41Z |
|
| dc.identifier |
c1a049b6-4392-4dd6-a7ad-b6aac8ec4b40 |
|
| dc.identifier |
10.1016/j.transci.2013.01.002 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/c1a049b6-4392-4dd6-a7ad-b6aac8ec4b40/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/101230 |
|
| dc.description |
Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature. © 2013 Elsevier Ltd. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Successful management of imatinib despite alopecia and nail necrosis |
|
| dc.type |
info:eu-repo/semantics/article |
|